title: Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
authors.forename: Zdenka
authors.initials: Z
authors.lastname: Haskova
authors.forename: Margaret N
authors.initials: MN
authors.lastname: Whitacre
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Dede
authors.forename: Judithann M
authors.initials: JM
authors.lastname: Lee
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Trulli
authors.forename: Marc
authors.initials: M
authors.lastname: Ciucci
authors.forename: John F
authors.initials: JF
authors.lastname: Toso
authors.forename: John R
authors.initials: JR
authors.lastname: White
authors.forename: Zdenka L
authors.initials: ZL
authors.lastname: Jonak
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology; D018951:Antigens, CD20 / Q000276:immunology; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D045744:Cell Line, Tumor / Q000187:drug effects / Q000637:transplantation; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000494:pharmacology; D000069283:Rituximab; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride; C527517:ofatumumab